Despite extensive research efforts to treat neurodegenerative disorders, no drugs targeting the WNT signaling pathway have been approved for clinical use.13 Taken together, our findings suggest that genistein is a small compound that targets the noncell-autonomous WNT5B-NFATc2-MMP14 signaling pathway and delays the progression of HD pathogenesis. This evidence concerns the gene NFATC2 and Huntington disease.